-
Krystal Biotech doses first subject in lung cancer drug trial
23 Apr 2024 11:50 GMT
US-based biotechnology company Krystal Biotech has dosed the first subject in the Phase I KYANITE-1 clinical trial for its inhaled oncology candidate, KB707, aimed at treating patients with locally advanced or metastatic solid lung tumours.
A modified HSV- …
-
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
17 Apr 2024 21:25 GMT
… treatment and the first approved gene therapy to treat children with … the long-term outcomes of gene therapies. Manufacturers come to the … are addressing paying for gene therapies is through new ways … to treat non-small cell lung cancer (NSCLC). It has a …
-
Targeted nanoparticle delivery of FZD4 decreases lung tumor growth and metastasis
17 Apr 2024 11:58 GMT
… the lung tumors, decreases intertumoral hypoxia and prevents lung cancer metastases.… FZD4 signaling using gene therapy had efficiently decreased lung cancer progression and … lung cancers. Using the Cancer Genome Atlas datasets, they showed that lung cancer …
-
Nanoparticle delivery of FZD4 to lung endothelial cells inhibits lung cancer progression and metastases
16 Apr 2024 21:51 GMT
… the lung tumors, decreases intertumoral hypoxia and prevents lung cancer metastases,… FZD4 signaling using gene therapy had efficiently decreased lung cancer progression and … lung cancers. Using the Cancer Genome Atlas datasets, they showed that lung cancer …
-
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
25 Apr 2024 17:47 GMT
… in non-small cell lung cancer with POSEIDON. Calquence total … outcomes, including radio conjugates, gene therapies and cell therapies. We… regulatory authorities OS in lung cancer is an important … to better partner with lung cancer oncologists or breast cancer …
-
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 Apr 2024 16:30 GMT
… lung tumor diagnosis. This delay could result in the diagnosis of lung tumors … 47;lung-tumor-market/ Lung Tumor Market – Regional Analysis The Lung Tumor Market … Gene Therapy, Cell-Based Immunotherapies, Others), By Cancer Type (Breast Cancer, Lung Cancer …
-
RTW Biotech invests in cell and gene therapy company Obsidian
05 Apr 2024 11:26 GMT
… it has backed cell and gene therapy-focused biotech Obsidian Therapeutics Inc … company specialising in cell and gene therapy, will use the proceeds for … melanoma and non-small cell lung cancer.
RTW shares were down 0 …
-
Genprex Expands Trial Sites For Reqorsa Therapy-Tecentriq Trial In Small Cell Lung Cancer; Stock Up
03 Apr 2024 20:23 GMT
… . (GNPX), a clinical-stage gene therapy company focused on cancer and … treat extensive-stage small cell lung cancer or ES-SCLC.
In … is an aggressive form of lung cancer that is presently incurable. … the treatment of small cell lung cancer.
Genprex has received U …
-
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
03 Apr 2024 19:43 GMT
… GNPX), a clinical-stage gene therapy company focused on developing life … enrollment from our other lung cancer clinical trial, we believe … further its pipeline of gene therapies in order to provide … to-treat-small-cell-lung-cancer-302106790.html
SOURCE Genprex, …
-
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
02 Apr 2024 16:42 GMT
… metastatic non-small cell lung cancer (NSCLC) in a … researchers reported that NPRL2 gene therapy induces anti-tumor activity … further its pipeline of gene therapies in order to … preclinical-data-with-nprl2-gene-therapy-utilizing-oncoprex-delivery-system …